PMN 286 Rev A

E L I X I R M E D I C A L C O R P O R A T I O N

INNOVATINGVA S C U L A R R E S T O R AT I O N TM

Pipeline

Elixir

Bioresorbable Scaffold Therapy – Why ?Bioresorbable Scaffold Therapy – Why ?

Our Technology - DESolveOur Technology - DESolve

PMN 286 Rev A

E L I X I R M E D I C A L C O R P O R A T I O N

ABOUT ELIXIR®

PMN 286 Rev A

ABOUT ELIXIR ®

E L I X I R M E D I C A L C O R P O R A T I O N 3

Elixir was founded in 2005and is located in Sunnyvale, California.

10Years

Elixir has consistently demonstrated the ability to out-engineer and out-innovate

traditional large companies.

PMN 286 Rev A

ABOUT ELIXIR ®

E L I X I R M E D I C A L C O R P O R A T I O N 4

20+Countries

Present in over 20 countries. Uninterrupted product supply.

CorporateHeadquarters

PMN 286 Rev A

ABOUT ELIXIR ®

3 Industry Encompassing Categories:

E L I X I R M E D I C A L C O R P O R A T I O N 5

Drug Eluting Stent (DES)1 ®

Drug Eluting Stent with Biodegradable Polymer Coating2 ®

Drug Eluting Bioresorbable Scaffold (BRS)3®

DESolve, DESyne BD and DESyne are CE Mark approved. Not available for sale in the U.S.DESolve, DESyne BD and DESyne are registered trademarks of Elixir Medical.

PMN 286 Rev A

E L I X I R M E D I C A L C O R P O R A T I O N 6

Bioresorbable Scaffold Therapy – Why ?

PMN 286 Rev A

PMN 286 Rev A

REVASCULARIZATION –EVOLUTION OF CORONARY STENTS

E L I X I R M E D I C A L C O R P O R A T I O N 7

*Fajadet Our Interventional Future PCR 2010

ANGIOPLASTY

1977 1986 1999 Today

Revascularization

Allows for natural arterial function

Restenosis (20% to 30%),* Recoil, Subacute thrombosis

PMN 286 Rev A

REVASCULARIZATION –EVOLUTION OF CORONARY STENTS

E L I X I R M E D I C A L C O R P O R A T I O N 8

*Fajadet Our Interventional Future PCR 2010

1977 1986 1999 Today

BARE METAL STENTS

Revascularization

Prevention of acute arterial recoil

Restenosis (15% to 50%),* injury to the endothelium may cause acute stent thrombosis

Permanent implant

PMN 286 Rev A

REVASCULARIZATION –EVOLUTION OF CORONARY STENTS

E L I X I R M E D I C A L C O R P O R A T I O N 9

1977 1986 1999 Today

DES

Revascularization

↓ Restenosis rate (10%)*

Long-term DAPT required

Late stent thrombosis

*Fajadet Our Interventional Future PCR 2010

Permanent implant

PMN 286 Rev A

BIORESORBABLE SCAFFOLDS

E L I X I R M E D I C A L C O R P O R A T I O N 10

1977 1986 1999 Today

Scaffold provides best-in-class DES drug elution

Short-term support is sufficient for acute gain and prevention of recoil

BRS MECHANICAL BENEFITS – DESIGN GOALS

Uncaging in a timely manner

PMN 286 Rev A

11E L I X I R M E D I C A L C O R P O R A T I O N 11

BIORESORBABLE SCAFFOLDS –

“UNCAGING” THE ARTERY

BIOLOGICAL BENEFITS

After resorption – no foreign body *

OTHER BENEFITS

Keep options open• CABG • Re-intervention

PMN 286 Rev A

Return of flexibility in artery for pulsatile flow

Return of vasomotion (ability of artery to contract/expand in response to hormonal influences)

PMN 286 Rev A

E L I X I R M E D I C A L C O R P O R A T I O N

TECHNOLOGY: DESolve®

PMN 286 Rev A P M N 2 4 7 R e v A

PLLA-based material with excellent durability, flexibility, proven biocompatibilityProfile: 150 µmDegrades in one year, resorbs in 2 yearsGood Radial strength, low acute recoilLow drug dose of Novolimus

Engineered to fulfill the promise of BRS

DESolve® BIORESORBABLE CORONARY SCAFFOLD

PMN 286 Rev A

DESolve® PERFORMANCE CRITERIA

FOR A FULLY B IORESORBABLE DEVICE

E L I X I R M E D I C A L C O R P O R A T I O N 14

Forrester JS, et al., J. Am. Coll. Cardiol. 17, 758 (1991)Oberhauser JP, et al., EuroInterv. 5, F15 (2009)DESolve is CE Mark approved. Not available for sale in the U.S.

1month 3 m 6 m 12 m 24 m

Drug Elution

Polymer Molecular

Weight Polymer Mass

PMN 286 Rev A

PMN 286 Rev A

DESolve® BIORESORBABLE CORONARY SCAFFOLD

EXCELLENT VESSEL CONFORMABILITY

E L I X I R M E D I C A L C O R P O R A T I O N 15

Case from A Abizaid, D Chamie, Instituto Dante Pazzanese, TCT 2012

97o

DESolve3,5 x 14mm DESolve (92o)

18 monthsPost-placementAt placementPre-placement

DESolve is CE Mark approved. Not available for sale in the U.S.

PMN 286 Rev A

MAIN BRANCH POST D ILATATION AND FRACTURE RESISTANCE

E L I X I R M E D I C A L C O R P O R A T I O N 16

*J Ormiston, TCT 2014Absorb is a registered trademark of Abbott Vascular.DESolve is CE Mark approved. Not available for sale in the U.S.

PMN 286 Rev A

UNDEREXPANSION: DESo lve ®

SELF-CORRECTION TO NOMINAL D IAMETER

E L I X I R M E D I C A L C O R P O R A T I O N 17

Data on file at Elixir Medical.Absorb is a registered trademark of Abbott Vascular.DESolve is CE Mark approved. Not available for sale in the U.S.

Pre-PCI Post-PCI 6-Month FU 18-Month FU 36-Month FU

C o u r t e s y o f D r . A . A b i z a i d , I n s t i t u t o D a n t e P a z z a n e s e d e C a r d i o l o g i a

S ã o P a u l o , B r a z i l

DESolve® DIFFERENTIATING PERFORMANCE CHARACTERISTICS

Post-Procedure

6-Month Follow-up

18-Month Follow-up

36-Month Follow-up

PMN 286 Rev A

E L I X I R M E D I C A L C O R P O R A T I O N 20

DESolve Pipeline

PMN 286 Rev A

PMN 286 Rev A

DESolve Pipel ine

E L I X I R M E D I C A L C O R P O R A T I O N 21

* MRVD ≥3.75 – 4.00mm^ J. Ormiston et al, An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition), EuroIntervention 2015;10-online publish-ahead-of-print February 2015.‡ Not to exceed .5mm beyond scaffold diameter.

DESolve and DESolve 100 are CE Mark approved. Not available for sale in the U.S.

Advancing BioresorbableScaffold Technology

PMN 286 Rev A

DESolveDESolve 100

DESolve100: Bioresorbable Coronar y

Scaf fold with 100µm strut thickness

CE mark approvedCurrently in clinical evaluationExpected launch in H2’2015

OCT analysis in porcine coronary model post implant

PMN 245

PMN 286 Rev A

DESolve+: First Scaf fold designed for AMI

DES

Underdeployed stent

PMN 286 Rev A

DESolve Coronar y Scaf folds

In DevelopmentCE Mark ApprovedCE Mark Approved

Available in 4.0mm diameter

Drug-eluting

Bioresorbable scaffold

DESolve FIMDESolve Nx

Dose: 5 µg/mm ofStent or Scaffold length

NovolimusPharmaceutical

Biodegradable polymer coating

Bioresorbable scaffold

Biodegradable polymer coating

Bioresorbable scaffold

PMN 286 Rev A

� First in Man Clinical Trial Planned for 2nd half 2015

Bioresorbable SFA Scaf fo ld

Design

Elixir SFA Covidien Protégé Everflex

Cook Zilver PTX

Radial Strength1

Elixir SFA Covidien Protégé Everflex

Cook Zilver PTX

Scaffold Stiffness1

More

conformable

1. Data on file at Elixir Medical, 1190-029N

Post Implant 1 Month 3 Month 6 Month

PMN 286 Rev A

VascularVascular

CarotidCarotid NeuroNeuro VenousVenous

NonvascularNonvascular

ENTENT PulmonaryPulmonary

El ix i r Is Pur su ing Other Ind icat ions

Outs ide o f Coronar y and Per iphera l

Currently in market research / market requirement definition phaseDevelopment efforts will begin in 2015 on the first of these indications

PMN 245Note: Pursuing development through license to Aigle and Cerona Medical